Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer. [electronic resource]
Producer: 20210129Description: 1156-1168 p. digitalISSN:- 1097-4644
- Apoptosis -- drug effects
- Benzodiazepinones -- pharmacology
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Drug Synergism
- Female
- Humans
- MAP Kinase Kinase 5 -- antagonists & inhibitors
- Mitogen-Activated Protein Kinase 7 -- antagonists & inhibitors
- Phosphatidylinositol 3-Kinases -- metabolism
- Phosphoinositide-3 Kinase Inhibitors -- pharmacology
- Piperazines -- pharmacology
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- Pyridones -- pharmacology
- Pyrimidines -- pharmacology
- Pyrimidinones -- pharmacology
- Signal Transduction -- drug effects
- Triple Negative Breast Neoplasms -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.